CoChat

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML

Open access
John, Samuel, Chen, Heyu, Deng, Mi, Gui, Xun, Wu, Guojin, Chen, Weina, Li, Zunling, Zhang, Ningyan, An, Zhiqiang, Zhang, Cheng Cheng · 2018 · Molecular Therapy
Cited by 138

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

To effectively improve treatment for acute myeloid leukemia (AML), new molecular targets and therapeutic approaches need to be identified. Chimeric antigen receptor (CAR)-modified T cells targeting tumor-associated antigens have shown promise in the treatment of some malignancies. However, CAR-T cell development for AML has been limited by lack of an antigen with high specificity for AML cells that is not present on normal hematopoietic stem cells, and thus will not result in myelotoxicity. Here we demonstrate that leukocyte immunoglobulin-like receptor-B4 (LILRB4) is a tumor-associated antigen highly expressed on monocytic AML cells. We generated a novel anti-LILRB4 CAR-T cell that displays high antigen affinity and specificity. These CAR-T cells display efficient effector function in vitro and in vivo against LILRB4 + AML cells. Furthermore, we demonstrate anti-LILRB4 CAR-T cells are not toxic to normal CD34 + umbilical cord blood cells in colony-forming unit assays, nor in a humanized hematopoietic-reconstituted mouse model. Our data demonstrate that anti-LILRB4 CAR-T cells specifically target monocytic AML cells with no toxicity to normal hematopoietic progenitors. This work thus offers a new treatment strategy to improve outcomes for monocytic AML, with the potential for elimination of leukemic disease while minimizing the risk for on-target off-tumor toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2018.08.001

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 138

Metadata

Authors
John, S., Chen, H., Deng, M., Gui, X., Wu, G., Chen, W., Li, Z., Zhang, N., An, Z., & Zhang, C. C.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2018-10
Volume
26
Issue
10
Pages
2487-2495
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2886509896
Cited by
138
References
6
FWCI
3.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. https://app.cochat.ai/papers/10.1016/j.ymthe.2018.08.001
The paper
John, S., Chen, H., Deng, M., Gui, X., Wu, G., Chen, W., Li, Z., Zhang, N., An, Z., & Zhang, C. C. (2018). A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2018.08.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.